FDA approved 46 drugs in 2017, a 21-year high; pilot program tests using home care to reduce emergency department visits; a look at how increasing prices, not increased use of services, has caused American healthcare spending to grow so much faster than peer nations.
In 2017, the FDA approved 46 new drugs, which was more than double the amount approved in 2016. According to Reuters, this represented a 21-year high for FDA drug approvals in 1 year, and the number does not include the first gene therapies approved, which are part of a different category. The FDA has been able to accelerate the approval process by using the breakthrough therapy designation.
A new pilot program in Washington, DC, is virtually connecting Medicaid patients who can’t or won’t visit the clinic to primary care. The program sends a medical assistant to the home to connect the patient with the clinic, according to NPR. The idea is to develop relationships with patients who aren’t going to the doctor’s office and reduce the use of unnecessary visits to the emergency department (ED). In addition, the DC council is considering a way to reimburse for these types of visits.
Just a few decades ago, American healthcare spending was closer to that of comparable nations. But today, the country spends almost twice as much. The New York Times blog The Upshot explains that the price, not the use, of healthcare in America is the problem. Americans are actually using the same amount of healthcare as people in peer countries—they just pay a lot more for those services. Research has shown that the growth in American healthcare spending is almost entirely from growth in prices and that US hospital prices are 60% higher than European prices.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More